- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000929
A Study of the Effects of Advantage 24 on the Rectum
Phase I Rectal Microbicide Study
The purpose of this study is to see if it is safe and acceptable for homosexual male couples, where both partners have the same HIV status, to use Advantage 24 during anal intercourse. Advantage 24 is a spermicide (a chemical that kills sperm).
Much research and development is being done with chemicals that can be controlled by the receptive partner to prevent the spread of HIV and other sexually transmitted diseases (STDs). Advantage 24 currently is used in the vagina as a form of birth control. The safety of Advantage 24 is particularly important for HIV-positive men because they have a greater chance of serious reaction to Advantage 24 due to other HIV-related conditions.
Study Overview
Detailed Description
Chemical barriers which can be controlled by the receptive partner to prevent transmission of HIV and other sexually transmitted diseases (STDs) are among the highest priorities for research and development. Advantage 24 is a contraceptive gel containing nonoxynol-9 (N-9). This study provides information on the safety of N-9 in a bioadhesive gel formulated for use by MSM during anal intercourse. Safety is assessed for both HIV-positive and HIV-negative men because HIV-positive men may be at increased risk for toxicity due to other HIV-related conditions.
Participants are divided into 4 cohorts depending on their serostatus and whether they are the insertive or receptive partner. Participants apply Advantage 24 once or twice a day for 5 weeks and 4 times a day for the sixth week. Check-in visits, which include a genital exam, are performed at Weeks 1, 2, 4, 5, and 7. More complete physical evaluations, including anoscopy for receptive partners and blood tests, are performed at Weeks 3, 6, and 8.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98104
- Univ of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Exclusion Criteria
Co-existing Condition:
Participants with the following symptoms or conditions are excluded:
- Positive HSV-2 serology (HIV-negative participants only).
- Positive syphilis by Venereal Disease Research Laboratory (VDRL) serology and Fluorescent Treponemal Antibody (FTA) or Microhemagglutination Assay (MHA).
Receptive partners with the following additional symptoms or conditions are excluded:
- Rectal gonorrhea or chlamydia by culture.
- Active rectal inflammation, ulceration, or fissures.
Insertive partners with the following additional symptoms or conditions are excluded:
- Penile or urethral irritation, rashes, or lesions.
- Penile or scrotal piercing.
Concurrent Medication:
Excluded for receptive partners:
-
Anticoagulant, including warfarin and heparin.
Participants with the following prior conditions are excluded:
- Sensitivity or irritative symptoms when using N-9 or when exposed to latex.
- Three or more Herpes Simplex 2 Virus (HSV-2) outbreaks within 12 months prior to screening (HIV-positive participants only).
- One or more HSV-2 outbreaks within 6 months prior to screening (HIV-positive participants only).
Receptive partners with the following additional prior conditions are excluded:
- Diagnosed inflammatory bowel disease, ulcerative colitis, Crohn's disease, or rectal malignancy.
- Diagnosed bleeding disorder, including hemophilia and thrombocytopenia.
- Rectal surgery including fistulectomy.
- Prosthetic heart valve or diagnosis of a valvular abnormality.
- Hemorrhoidectomy within 6 months prior to screening.
- Rectal burning, tenesmus, bleeding, or irritation in the week prior to screening.
- Diarrhea (more than 3 stools per day) in the week prior to screening.
- Use of rectally-inserted sex toys, practiced receptive fisting, or rectal douching in the week prior to screening.
Insertive partners with the following additional prior conditions are excluded:
Urethral burning or discharge in the week prior to screening.
Prior Medication:
Excluded for receptive partners:
Use of laxatives in the week prior to screening.
Participants meet the following criteria:
- HIV-negative or HIV-positive; participant's partner must be the same serostatus.
- Plan to have anal intercourse only with the study partner for the duration of the study. During all episodes in which Advantage 24 is used, one partner is exclusively insertive and the other partner is exclusively receptive.
- Sexual partner of at least 3 months is eligible and agrees to participate.
- Agree to use non-N-9 lubricant and condoms for all episodes of anal intercourse.
- Avoid use of Advantage 24 for purposes other than specified by the protocol.
Receptive partners meet the following additional criteria:
- Plan to have receptive anal intercourse with the study partner with Advantage 24 applied rectally, and using N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week).
- Agree to apply the specified amount of Advantage 24 daily to the rectum.
- Avoid use of laxatives, use of rectally-inserted sex toys, receptive fisting, and rectal douching.
Insertive partners meet the following additional criteria:
- Plan to have insertive anal intercourse with the study partner with Advantage 24 applied to the glans of the penis, and using non-N-9 lubricant and condoms, at the couple's usual frequency (at least 3 times per week).
- Agree to apply the specified amount of Advantage 24 daily to the penis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
Collaborators and Investigators
Investigators
- Study Chair: Connie Celum
- Study Chair: Susan Buchbinder
Study record dates
Study Major Dates
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Physiological Effects of Drugs
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Contraceptive Agents, Male
- Spermatocidal Agents
- Antispermatogenic Agents
- Nonoxynol
Other Study ID Numbers
- HIVNET 008
- 11715 (DAIDS ES)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Nonoxynol-9
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPregnancyUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
CONRADUnited States Agency for International Development (USAID); FHI 360; ReProtect...Completed
-
Johns Hopkins UniversityCompleted
-
CONRADCompletedContraceptionUnited States, Dominican Republic
-
CONRADCompletedVaginal Infections | Vaginal InflammationUnited States
-
Shanghai Institute of Planned Parenthood ResearchFudan University; International Peace Maternity and Child Health Hospital; Shanghai... and other collaboratorsCompleted
-
Taiwan Sunpan Biotechnology Development Co., Ltd.Virginia Contract Research Organization Co., Ltd.CompletedMetastatic Colorectal CancerTaiwan
-
Bernafon AGCompletedHearing LossSwitzerland
-
London School of Hygiene and Tropical MedicineMerck Sharp & Dohme LLC; Public Health England; University of CambridgeActive, not recruitingHuman Papillomavirus VaccineGambia